Euretina Logo, Links to homepage.
Euretina Logo, Links to homepage.

Anatomical and functional results of dexamethasone intravitreal implant in diabetic macular edema patients.

Author: Almudena Moreno Martínez (Spain)

Co-authors: Cristina Blanco Marchite, Antonio Donate Tercero, Francisco López Martínez, Eva María González Aquino, Carlos Cava Valenciano, Sergio Copete Piqueras

Purpose

To assess functional outcomes of intravitreal dexamethasone implant in eyes with diabetic macular edema (DME), naïve or without adequately respond to antivascular endothelial growth factor inhibitors (AntiVEGF).

Setting/Venue

Department of Ophthalmology. Complejo Hospitalario Universitario de Albacete (CHUA), Spain

Methods

Retrospective real-world study conducted on consecutive DME patients who underwent treatment with a dexamethasone implant injection and were controlled at 2, 6 and 12 months. Subjects were divided in groups: naïve patients and non-responders to previously treated eyes with antiVEGF injections. Primary endpoints were best-corrected visual acuity (BCVA) and central retinal thickness (CRT).

Results

A total of 128 eyes (31 naïve) were finally included in the study, with a mean age of 64.07 ± 10.24 years. At baseline, there were no statistically significant differences between gender, BCVA, CRT, type of diabetes mellitus, DME subtype and state of the lens. At month 2, the BCVA (logMAR) changed from 0.4 ± 0.61 to 0.3 ± 0.37 and 0.52 ± 0.50 to 0.52 ± 0.4 in naïve and previously treated, respectively (p<0.05). At month 6 and 12, there is no difference between groups with final visual acuity of 0.52 ± 0.4 and 0.52 ± 0.7 in naïve and previously treated group, respectively (p=0.15). CRT improved at month 2, 6 and 12 in both groups (p<0.05). 21 eyes (72.41%) and 62 eyes (71.26%) improved in 20% the CRT in naïve and previously treated group, respectively, without differences between groups at 2 months. 40% of patients improved in 20% the CRT in both groups at month 6 (p=0.68) and 12 (p=0.83).

Conlusions

In our study, there were no differences in functional and anatomical response to dexamethasone implant in naive patients versus previously treated patients.

Financial Disclosure

We have no financial interest.

Comments

-

IMPORTANT INFORMATION

Beware of fraudulent websites, emails and hotel booking offers

www.euretina.org is the only official website of the European Society of Retina Specialists.
 
Please be wary of websites, emails from third-party agencies using similar names, addresses or branding and purporting to represent Euretina.
 
This includes websites or companies offering Congress registration, hotel accommodation or travel services while claiming to be affiliated with Euretina.

Should you use any website other than www.euretina.org, or book accommodation through an unauthorised third-party site, you may be charged significantly more than the official registration fee, your hotel booking may not be valid, and you may not be registered for the event at all.
 
If you have any questions in relation to registration or accommodation for the Congress, these should only be directed to [email protected].